Date: 2011-10-03
Type of information: Licensing agreement
Compound: Stimuvax® (BLP25 liposome vaccine)
Company: Merck KGaA, Merck Serono (Germany) Ono Pharmaceutical (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
development
commercialisation
Action mechanism: Stimuvax® is a cancer immunotherapy targeting the tumor antigen, MUC-1.
Disease: non-small cell lung cancer
Details: Ono Pharmaceutical has signed an agreement with Merck to license for co-development and co-marketing Stimuvax® in Japan, a novel cancer immunotherapy, globally developed by Merck Serono, the biopharmaceutical division of Merck KGaA. A Phase II study for Stimuvax® (EMR63325-009) is being conducted by Merck Serono Co., Ltd., a Japanese subsidiary of Merck KGaA, for the treatment of non-small cell lung cancer in Japan (Phase III studies are in progress outside Japan). Merck KGaA obtained the exclusive worldwide licensing rights from Oncothyreon Inc., Seattle, Washington, USA.
Financial terms: Ono obtained rights to co-develop and co-market Stimuvax® (BLP25 liposome vaccine) in Japan together with Merck. Under the terms of the agreement, Ono will pay to Merck 5 million euros as an upfront payment.
Latest news:
